Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

BACKGROUND: This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin’s lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurczak, W, Zinzani, P L, Gaidano, G, Goy, A, Provencio, M, Nagy, Z, Robak, T, Maddocks, K, Buske, C, Ambarkhane, S, Winderlich, M, Dirnberger-Hertweck, M, Korolkiewicz, R, Blum, K A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961010/
https://www.ncbi.nlm.nih.gov/pubmed/29444231
http://dx.doi.org/10.1093/annonc/mdy056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961010/
https://www.ncbi.nlm.nih.gov/pubmed/29444231
http://dx.doi.org/10.1093/annonc/mdy056

Ejemplares similares